Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
05 août 2020 09h25 HE
|
Corbus Pharmaceuticals Holdings, Inc.
12-month, double-blind, placebo-controlled, multi-national study enrolled 176 participantsTopline results expected in fourth quarter of 2021 Dermatomyositis is a rare, systemic autoimmune disease with...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences
03 août 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...
Corbus Pharmaceuticals to Report Second Quarter Results on August 6, 2020
30 juil. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Management to host conference call and webcast on Thursday, August 6 at 8:30 a.m. ET Norwood, MA, July 30, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors
08 juil. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several key data readouts this summer Norwood, MA,...
Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
27 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and JapanThere are no FDA-approved...
Corbus Pharmaceuticals Announces Publication of Two Abstracts at EULAR 2020 E-Congress
22 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
First abstract highlights pre-clinical data linking lenabasum’s mechanism of action to inhibiting inflammasome activationSecond abstract outlines baseline characteristics of RESOLVE-1 patients in EU ...
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
04 mai 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
18 nov. 2019 08h17 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation...
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
11 nov. 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile...
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019
04 nov. 2019 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Thursday, November 7 at 8:30 a.m. ET - Norwood, MA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:...